Cargando…

What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study

BACKGROUND: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills (‘polypills’) potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Jan, Stephen, Usherwood, Tim, Brien, Jo Anne, Peiris, David, Rose, John, Hayman, Noel, Howard, Kirsten, Redfern, Julie, Laba, Tracey, Cass, Alan, Patel, Anushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211054/
https://www.ncbi.nlm.nih.gov/pubmed/22080542
http://dx.doi.org/10.1136/bmjopen-2011-000372
_version_ 1782215797945401344
author Jan, Stephen
Usherwood, Tim
Brien, Jo Anne
Peiris, David
Rose, John
Hayman, Noel
Howard, Kirsten
Redfern, Julie
Laba, Tracey
Cass, Alan
Patel, Anushka
author_facet Jan, Stephen
Usherwood, Tim
Brien, Jo Anne
Peiris, David
Rose, John
Hayman, Noel
Howard, Kirsten
Redfern, Julie
Laba, Tracey
Cass, Alan
Patel, Anushka
author_sort Jan, Stephen
collection PubMed
description BACKGROUND: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills (‘polypills’) potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy. METHODS/DESIGN: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour. ETHICS AND DISSEMINATION: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations.
format Online
Article
Text
id pubmed-3211054
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-32110542011-12-01 What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study Jan, Stephen Usherwood, Tim Brien, Jo Anne Peiris, David Rose, John Hayman, Noel Howard, Kirsten Redfern, Julie Laba, Tracey Cass, Alan Patel, Anushka BMJ Open Health Services Research BACKGROUND: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills (‘polypills’) potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy. METHODS/DESIGN: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour. ETHICS AND DISSEMINATION: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations. BMJ Group 2011-10-27 /pmc/articles/PMC3211054/ /pubmed/22080542 http://dx.doi.org/10.1136/bmjopen-2011-000372 Text en © 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Health Services Research
Jan, Stephen
Usherwood, Tim
Brien, Jo Anne
Peiris, David
Rose, John
Hayman, Noel
Howard, Kirsten
Redfern, Julie
Laba, Tracey
Cass, Alan
Patel, Anushka
What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
title What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
title_full What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
title_fullStr What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
title_full_unstemmed What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
title_short What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
title_sort what determines adherence to treatment in cardiovascular disease prevention? protocol for a mixed methods preference study
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211054/
https://www.ncbi.nlm.nih.gov/pubmed/22080542
http://dx.doi.org/10.1136/bmjopen-2011-000372
work_keys_str_mv AT janstephen whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT usherwoodtim whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT brienjoanne whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT peirisdavid whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT rosejohn whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT haymannoel whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT howardkirsten whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT redfernjulie whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT labatracey whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT cassalan whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy
AT patelanushka whatdeterminesadherencetotreatmentincardiovasculardiseasepreventionprotocolforamixedmethodspreferencestudy